1. Home
  2. PCRX vs FTH Comparison

PCRX vs FTH Comparison

Compare PCRX & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

BUY

Current Price

$36.35

Market Cap

1.0B

Sector

Health Care

ML Signal

BUY

Logo Faeth Therapeutics Inc. Common Stock

FTH

Faeth Therapeutics Inc. Common Stock

BUY

Current Price

$19.37

Market Cap

835.7M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
PCRX
FTH
Founded
2006
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
835.7M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
PCRX
FTH
Price
$36.35
$19.37
Analyst Decision
Hold
Strong Buy
Analyst Count
9
16
Target Price
$33.57
★ $56.14
AVG Volume (30 Days)
★ 2.1M
331.0K
Earning Date
11-05-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 107.44
N/A
EPS
★ 0.19
N/A
Revenue
★ $541,533,000.00
N/A
Revenue This Year
$3.84
N/A
Revenue Next Year
$4.73
N/A
P/E Ratio
$191.29
★ N/A
Revenue Growth
★ 26.04
N/A
52 Week Low
$18.80
$17.50
52 Week High
$36.67
$42.14

Technical Indicators

Market Signals
Indicator
PCRX
FTH
Relative Strength Index (RSI) 83.97 29.10
Support Level $21.78 N/A
Resistance Level N/A $36.63
Average True Range (ATR) 0.40 2.32
MACD 0.89 -0.72
Stochastic Oscillator 97.44 11.64

Price Performance

Historical Comparison
PCRX
FTH

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About FTH Faeth Therapeutics Inc. Common Stock

Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.

Share on Social Networks: